MND-2119 Phase 3 Study to Evaluate the Efficacy and Safety of MND-2119 Compared to EPADEL CAPSULES 300 in Patients With Hypertriglyceridemia
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Sponsors Mochida Pharmaceutical
- 30 Jul 2019 Status changed from recruiting to completed.
- 24 Oct 2018 Status changed from not yet recruiting to recruiting.
- 10 Oct 2018 New trial record